The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.
…
Articles by : Ron Shinkman,
U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on
…
340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.
…
Drug manufacturer Merck says it is imposing mandatory conditions on 340B pricing when hospitals use contract pharmacies due to “very low” participation in its voluntary 340B program integrity initiative.
Groups that represent hospitals in the drug discount program say Merck
…
President Biden has nominated current White House Office of Management and Budget (OMB) General Counsel Sam Bagenstos to be the U.S. Health and Human Services Department (HHS) General Counsel—a post that has had a growing role in defending the 340B
…
Wisconsin Gov. Tony Evers (D) is pushing for passage of a package of 13 “Less for Rx” bills to control prescription drug costs, including one to eliminate payer and pharmacy benefit manager (PBM) discrimination against certain 340B covered entities.
The
…
U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B
…
A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.
Federal spending legislation that President Trump signed into law last Dec. 27 included a
…
Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.
“Kalderos is urging a rapid federal response to protect these hospitals,” the company said in a July 23
…
Hospitals groups were deeply disappointed last week with the U.S. Centers for Medicare & Medicaid Services’ (CMS) proposal to continue a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs in place since 2018.
Another provision
…